370 related articles for article (PubMed ID: 32748171)
1. Targeting the immune milieu in gastrointestinal cancers.
Turkes F; Mencel J; Starling N
J Gastroenterol; 2020 Oct; 55(10):909-926. PubMed ID: 32748171
[TBL] [Abstract][Full Text] [Related]
2. Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer.
Abolarinwa BA; Ibrahim RB; Huang YH
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540435
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in the neoadjuvant treatment of gastrointestinal tumors: is the time ripe?
Gervaso L; Ciardiello D; Oliveira RA; Borghesani M; Guidi L; Benini L; Algeri L; Spada F; Zampino MG; Cella CA; Fazio N
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38782539
[TBL] [Abstract][Full Text] [Related]
4. Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.
Bilgin B; Sendur MA; Bülent Akıncı M; Şener Dede D; Yalçın B
Curr Med Res Opin; 2017 Apr; 33(4):749-759. PubMed ID: 28055269
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy-based combination strategies for treatment of gastrointestinal cancers: current status and future prospects.
Zhou C; Zhang J
Front Med; 2019 Feb; 13(1):12-23. PubMed ID: 30796606
[TBL] [Abstract][Full Text] [Related]
6. Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials.
Hall PE; Schmid P
Expert Opin Emerg Drugs; 2021 Jun; 26(2):131-147. PubMed ID: 33870839
[No Abstract] [Full Text] [Related]
7. Current approaches to immunotherapy in noncolorectal gastrointestinal malignancies.
Jesus VHF; Felismino TC; Barros E Silva MJ; Souza E Silva V; Riechelmann RP
Clinics (Sao Paulo); 2018 Oct; 73(suppl 1):e510s. PubMed ID: 30365605
[TBL] [Abstract][Full Text] [Related]
8. CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers.
Harvey JB; Phan LH; Villarreal OE; Bowser JL
Front Immunol; 2020; 11():508. PubMed ID: 32351498
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in Gastrointestinal Cancers.
Procaccio L; Schirripa M; Fassan M; Vecchione L; Bergamo F; Prete AA; Intini R; Manai C; Dadduzio V; Boscolo A; Zagonel V; Lonardi S
Biomed Res Int; 2017; 2017():4346576. PubMed ID: 28758114
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitors in the Treatment of Gastrointestinal Malignancies: A Review of Current and Future Therapies.
Hsu A; Mendelson L; Almhanna K
R I Med J (2013); 2020 Apr; 103(3):33-37. PubMed ID: 32236159
[TBL] [Abstract][Full Text] [Related]
11.
Li L; Li M; Jiang Z; Wang X
Cells; 2019 Jul; 8(7):. PubMed ID: 31277418
[TBL] [Abstract][Full Text] [Related]
12. Radiation and Immunotherapy in Upper Gastrointestinal Cancers: The Current State of Play.
Donlon NE; Power R; Hayes C; Davern M; Reynolds JV; Lysaght J
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499003
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1.
Lefler DS; Snook AE; Bashir B
Immunotherapy; 2022 Aug; 14(11):885-902. PubMed ID: 35694998
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in Gastrointestinal Malignancies.
Mizrahi J; Pant S
Adv Exp Med Biol; 2020; 1244():93-106. PubMed ID: 32301012
[TBL] [Abstract][Full Text] [Related]
15. Targeting the tumour immune microenvironment for cancer therapy in human gastrointestinal malignancies.
Zhang Y; Xu J; Zhang N; Chen M; Wang H; Zhu D
Cancer Lett; 2019 Aug; 458():123-135. PubMed ID: 31121212
[TBL] [Abstract][Full Text] [Related]
16. Current status of immunotherapy in gastrointestinal malignancies.
Lorenzen S; Lordick F; Loosen SH; Tacke F; Trautwein C; Roderburg C; Ettrich TJ; Perkhofer L; Reinacher-Schick A; Stein A
Z Gastroenterol; 2020 Jun; 58(6):542-555. PubMed ID: 32018315
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for gastrointestinal malignancies.
Toomey PG; Vohra NA; Ghansah T; Sarnaik AA; Pilon-Thomas SA
Cancer Control; 2013 Jan; 20(1):32-42. PubMed ID: 23302905
[TBL] [Abstract][Full Text] [Related]
18. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity.
Lee WS; Yang H; Chon HJ; Kim C
Exp Mol Med; 2020 Sep; 52(9):1475-1485. PubMed ID: 32913278
[TBL] [Abstract][Full Text] [Related]
19. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Bai J; Liang P; Li Q; Feng R; Liu J
Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
[TBL] [Abstract][Full Text] [Related]
20. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
